Kiniksa Pharmaceuticals, Ltd.

KNSA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$73.41-1.25%

2026-08-03

Financials

Valuation Metrics

Kiniksa Pharmaceuticals, Ltd.'s Market Cap is $5.65B. At end of 2025 it was $3.06B. Ranked #1310 of 3,112 in US market (top 42%), #441 of 1,445 on NASDAQ (top 31%), #75 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$5.65B	US#1,310/3,112 Sec#75/269
Revenue	$841M	US#2,039/3,112 Sec#60/269
Net Income	$81M	US#1,681/3,112 Sec#59/269
Total Assets	$896M	US#2,493/3,112 Sec#104/269
Net Assets	$654M	US#2,067/3,112 Sec#84/269
Value
P/E	70.02x	US#1,983/3,112 Sec#63/269
P/B	8.63x	US#2,536/3,112 Sec#197/269
PEG	1.64x	US#993/3,112 Sec#33/269
P/S	6.72x	US#2,475/3,112 Sec#101/269
EV/EBITDA	49.11x	US#2,349/3,112 Sec#77/269
FCF Yield	3.24%	US#1,710/3,112 Sec#57/269
Profitability
ROE	12.33%	US#1,087/3,112 Sec#52/269
ROA	9.00%	US#529/3,112 Sec#38/269
Op. Margin	11.92%	US#1,469/3,112 Sec#60/269
Revenue Growth	55.36%	US#272/3,112 Sec#54/269
Earnings Growth	42.62%	US#619/3,112 Sec#30/269
Financial Health
Debt Ratio	36.99%	US#422/3,112 Sec#121/269
Total Debt	$9M	US#2,796/3,112 Sec#203/269
FCF	$183M	US#1,397/3,112 Sec#48/269
Cash	$176M	US#1,816/3,112 Sec#126/269
Current Ratio	3.07x	US#780/3,112 Sec#193/269
Net Debt/EBITDA	-1.49x	US#239/3,112 Sec#19/269
Performance
1Y Return	129.55%	US#216/3,112 Sec#62/269
1M Return	13.76%	US#341/3,112 Sec#14/269
From 52W High	-11.49%	US#1,151/3,112 Sec#65/269
1Y MDD	-21.12%	US#784/3,112 Sec#36/269
Trading
Volume	780,852 shares	US#1,707/3,112 Sec#164/269
Trading Value	$57M	US#1,272/3,112 Sec#75/269
Per Share
EPS	$0.80	US#1,702/3,112 Sec#57/269
BPS	$7.65	US#1,971/3,112 Sec#91/269